TGFB1 and breast cancer: In summary, our study suggests that doxorubicin at certain dosages can promote breast cancer invasion and metastasis in part through its ability to activate TGFβ signaling, which in turn generates stem-like cancer cells with increased drug resistance through an EMT process.